A detailed history of Clarius Group, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Clarius Group, LLC holds 10,000 shares of SAGE stock, worth $55,700. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,000
Previous 10,000 -0.0%
Holding current value
$55,700
Previous $108,000 33.33%
% of portfolio
0.01%
Previous 0.01%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 29, 2024

SELL
$17.1 - $22.26 $16,997 - $22,126
-994 Reduced 9.04%
10,000 $216,000
Q3 2023

Oct 19, 2023

BUY
$16.75 - $48.98 $4,020 - $11,755
240 Added 2.23%
10,994 $226,000
Q4 2022

Jan 25, 2023

BUY
$32.2 - $43.61 $901 - $1,221
28 Added 0.26%
10,754 $410,000
Q3 2022

Oct 24, 2022

BUY
$32.28 - $43.27 $17,721 - $23,755
549 Added 5.39%
10,726 $420,000
Q2 2022

Aug 10, 2022

BUY
$27.52 - $37.99 $280,071 - $386,624
10,177 New
10,177 $329,000
Q4 2020

Jan 15, 2021

SELL
$58.41 - $89.06 $2.07 Million - $3.16 Million
-35,500 Closed
0 $0
Q4 2019

Jan 22, 2020

BUY
$60.18 - $154.77 $2.14 Million - $5.49 Million
35,500 New
35,500 $2.66 Million
Q4 2017

Feb 09, 2018

SELL
$60.72 - $167.34 $7.84 Million - $21.6 Million
-129,068 Closed
0 $0
Q3 2017

Nov 07, 2017

BUY
$61.4 - $88.52 $7.92 Million - $11.4 Million
129,068
129,068 $8.04 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $331M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Clarius Group, LLC Portfolio

Follow Clarius Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clarius Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clarius Group, LLC with notifications on news.